Allakos Inc. (ALLK)
NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
As of 12:41PM EDT. Market open.
| Previous close | 1.2900 |
| Open | 1.2100 |
| Bid | 1.1800 x 100 |
| Ask | 1.2000 x 100 |
| Day's range | 1.1700 - 1.2300 |
| 52-week range | 0.9800 - 5.6400 |
| Volume | |
| Avg. volume | 579,200 |
| Market cap | 105.811M |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -2.1400 |
| Earnings date | 07 Aug 2024 - 12 Aug 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 2.90 |
GlobeNewswireAllakos Provides Business Update and Reports First Quarter 2024 Financial Results
SAN CARLOS, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing antibodies for the treatment of allergic, inflammatory and proliferative diseases, today provided a business update and reported financial results for the first quarter ended March 31, 2024. Recent Allakos Events Completed dosing in the single ascending dose (SAD) cohorts and multiple ascending dose (MAD) cohorts of the randomized, double-blind, placebo-controlled
Simply Wall St.With 55% ownership of the shares, Allakos Inc. (NASDAQ:ALLK) is heavily dominated by institutional owners
Key Insights Institutions' substantial holdings in Allakos implies that they have significant influence over the...
ZacksAllakos (ALLK): Strong Industry, Solid Earnings Estimate Revisions
Allakos (ALLK) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
© 2024 Yahoo. All rights reserved.